Drug intelligence / Profile preview

ONC-001

Development stage: Preclinical
Lead developer: RapaFusyn Pharmaceuticals
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Oral

Overview

ONC-001 is an early-stage oncology drug candidate being developed by RapaFusyn Pharmaceuticals. It is discovered using the company's proprietary RapaGlues™ platform, which focuses on the development of rapamycin-based macrocyclic molecular glues. These molecules are designed to modulate protein-protein interactions, acting either as molecular glue degraders or non-degrading molecular glues to address targets that are traditionally difficult to drug. ONC-001 is currently in the hit identification to hit-to-lead stage of preclinical development for unspecified cancer indications.

Targets

FKBP1A

Beyond the preview

Go deeper on ONC-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONC-001.

Explore the full profile